PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
PTC Therapeutics reported Q3 2026 total revenue of $357.8 million, up roughly 70% year-over-year, with net product revenue more than doubling to $275.9 million from $131.0 million. The Sephience launch drove the quarter with $181.9 million in revenue (up 20% sequentially) and over 2,000 active patients worldwide; Evrysdi royalties added $81.7 million. Full-year 2026 guidance was raised: total revenue to $1.29-$1.32 billion and product revenue to $960-$990 million from $850-$950 million.
Key figures
- Revenue
- 357807000
- Guidance
- FY2026 total revenue raised to $1.29-$1.32B; product revenue raised to $960-$990M from $850-$950M
- Revenue Yoy
- 70%
- Gaap rnd
- 105353000
- Gaap sga
- 80081000
- Nongaap rnd
- 94874000
- Nongaap sga
- 66733000
- Product revenue
- 275894000
- Royalty revenue
- 81684000
- Sephience revenue
- 181900000
- Shares outstanding
- 83535767
- Sephience active patients
- over 2,000
- Cash and marketable securities
- 2127918000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.